Protein Summary
Multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone chaperoning. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T-lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF-mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins; however, isoform 2 specific activity is higher. The protein encoded by this gene inhibits acetylation of nucleosomes, especial ...more
- ENST00000322030
- ENSP00000318012
- ENSG00000119335
- ENST00000372686
- ENSP00000361771
- ENST00000372692
- ENSP00000361777
- ENST00000409104
- ENSP00000387321
- 2PP2A
- IGAAD
- MRD58
- TAF-I
- I2PP2A
- IPP2A2
- PHAPII
- TAF-IBETA
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
co-expressed gene | 1 | ||
kinase perturbation | 1 | ||
disease perturbation | 0.99 | ||
hub protein | 0.99 | ||
interacting protein | 0.99 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 132.88 (req: < 5)
Gene RIFs: 126 (req: <= 3)
Antibodies: 347 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 132.88 (req: >= 5)
Gene RIFs: 126 (req: > 3)
Antibodies: 347 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 12
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0